Literature DB >> 8336691

Final results: Medicare influenza vaccine demonstration--selected states, 1988-1992.

.   

Abstract

Pneumonia and influenza (P&I) are the sixth leading cause of death in the United States, and persons aged > or = 65 years and persons with chronic conditions (e.g., lung or heart disease, diabetes, or cancer) are at greatest risk for P&I. During major epidemics, hospitalization rates for persons at highest risk may increase twofold to fivefold. However, only 30% of persons aged > or = 65 years responding to CDC's National Health Interview Survey for 1989 reported having received the influenza vaccine during the previous year. In 1988, the Health Care Financing Administration (HCFA) and CDC began a congressionally mandated 4-year demonstration project to evaluate the cost-effectiveness to Medicare of providing influenza vaccine to Medicare beneficiaries. This report presents final results of the Medicare Influenza Vaccine Demonstration conducted during 1988-1992.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8336691

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  6 in total

Review 1.  The value of influenza and pneumococcal vaccines in the elderly.

Authors:  A S Monto; M S Terpenning
Journal:  Drugs Aging       Date:  1996-06       Impact factor: 3.923

2.  The impact of the Medicare Influenza Demonstration Project on influenza vaccination in a county in Massachusetts, 1988-1992.

Authors:  P Etkind; M Simon; S Shannon; C Bottum; R Goldstein; B Werner; S Cheney
Journal:  J Community Health       Date:  1996-06

Review 3.  Influenza vaccines. A reappraisal of their use.

Authors:  A M Palache
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

4.  The health and economic benefits of influenza vaccination for healthy and at-risk persons aged 65 to 74 years.

Authors:  K L Nichol; M Goodman
Journal:  Pharmacoeconomics       Date:  1999       Impact factor: 4.981

5.  Evaluation of a simple office-based strategy for increasing influenza vaccine administration and the effect of differing reimbursement plans on the patient acceptance rate.

Authors:  P A Merkel; G C Caputo
Journal:  J Gen Intern Med       Date:  1994-12       Impact factor: 5.128

Review 6.  Key policy and programmatic factors to improve influenza vaccination rates based on the experience from four high-performing countries.

Authors:  George Kassianos; Ashis Banerjee; Florence Baron-Papillon; Alan W Hampson; Janet E McElhaney; Allison McGeer; Thierry Rigoine de Fougerolles; Mitch Rothholz; Holly Seale; Litjen J Tan; Angus Thomson; Olivier Vitoux
Journal:  Drugs Context       Date:  2021-01-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.